コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 h pain during ambulation, which is known as "intermittent claudication".
2 improve morbidity, including the symptoms of intermittent claudication.
3 e heart failure, stroke, incident angina, or intermittent claudication.
4 ral times more common in the population than intermittent claudication.
5 ymptoms that are not consistent with classic intermittent claudication.
6 is recommended as a first-line treatment for intermittent claudication.
7 establish the role for revascularization in intermittent claudication.
8 ategies to improve mobility in patients with intermittent claudication.
9 ion, and leukocyte adhesion in patients with intermittent claudication.
10 ife after 1 year in unselected patients with intermittent claudication.
11 not an effective treatment for patients with intermittent claudication.
12 patients with peripheral artery disease and intermittent claudication.
13 formance or quality of life in patients with intermittent claudication.
14 scores of PAD participants with and without intermittent claudication.
15 s with peripheral arterial disease (PAD) and intermittent claudication.
16 se rates of ischemic events in patients with intermittent claudication.
17 ity-based physical activity in patients with intermittent claudication.
18 mproves walking performance in patients with intermittent claudication.
19 tinnitus but has some effect on dementia and intermittent claudication.
20 capacity in patients with moderate-to-severe intermittent claudication.
21 ents between May 2010 and February 2013 with intermittent claudication.
22 cipants with peripheral arterial disease had intermittent claudication.
23 erotic peripheral arterial disease (PVD) and intermittent claudication.
24 singly been used for patients with disabling intermittent claudication.
25 safe and well tolerated for the treatment of intermittent claudication.
26 l for treatment of stable, moderately severe intermittent claudication.
27 e and acceptable treatment for patients with intermittent claudication.
28 , and cardiovascular events in patients with intermittent claudication?
29 e uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4%
34 y in peripheral artery disease patients with intermittent claudication after a home-based exercise pr
36 participants, including 36 PAD patients with intermittent claudication and 20 matched controls, under
37 e characteristics compared with persons with intermittent claudication and a sedentary, asymptomatic,
38 tified as having PAD at baseline if they had intermittent claudication and an ankle brachial index of
39 s lower extremity pain, which may present as intermittent claudication and atypical leg pain, and, in
42 Global Study enrolled 1535 participants with intermittent claudication and/or ischemic rest pain caus
43 ents with stenosis or occlusion, symptoms of intermittent claudication, and maximum walking distance
44 ties, resulting in skeletal muscle ischemia, intermittent claudication, and, in more severe stages of
47 x <0.9 assessed at regular examinations, new intermittent claudication assessed by annual surveillanc
53 an-Meier analysis with subgroup analysis for intermittent claudication, chronic limb-threatening isch
54 erm effectiveness of combination therapy for intermittent claudication, compared with supervised exer
56 improves health-related quality of life and intermittent claudication distance after 1 year in patie
58 us placebo for 6 months in 133 subjects with intermittent claudication due to PAD in a single-center
60 5 subjects with unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill
61 ivation, which can occur in the condition of intermittent claudication during exertion, an exaggerate
62 diabetes and peripheral artery disease with intermittent claudication (Fontaine stage IIa, able to w
63 model was used to compute the probability of intermittent claudication for specified levels of risk f
64 rospectively followed 255 male patients with intermittent claudication from the CAVASIC Study during
65 th peripheral arterial disease (PAD) without intermittent claudication have been established as benef
66 ge, body mass index, diabetes mellitus, sex, intermittent claudication, heart rate, estimated glomeru
67 ssociations between respiratory diseases and intermittent claudication (i.e. pain in the leg during w
68 rterial disease patients included those with intermittent claudication (IC) (n = 23) and critical lim
69 ation strategies in patients presenting with intermittent claudication (IC) and critical limb ischemi
70 ave occurred, but it remains unclear whether intermittent claudication (IC) incidence and mortality r
77 commercially available for the treatment of intermittent claudication in 2015 and 2012, respectively
78 ical trial including 190 adults with PAD and intermittent claudication in 6 hospitals in the United K
85 th a diagnosis of peripheral artery disease, intermittent claudication, leg revascularisation, and le
89 tension (n=2), worsening hypertension (n=1), intermittent claudication (n=1) and wound infection (n=1
90 ategorized into leg symptom groups including intermittent claudication (n=215) and always asymptomati
94 n a 2:1 ratio, 476 patients with symptomatic intermittent claudication or ischemic pain while at rest
95 randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attribut
96 pproach to the patient with symptom-limiting intermittent claudication or limb-threatening ischemia b
97 who subsequently developed symptomatic PAD (intermittent claudication or need for revascularization)
99 site of a primary end point event or angina, intermittent claudication, or transient ischemic attack;
100 in the secondary outcome of disease-specific Intermittent Claudication Questionnaire score at 4 month
101 trial (Invasive Revascularization or Not in Intermittent Claudication) randomized patients with mild
102 0 lower extremities) with known or suspected intermittent claudication referred for lower extremity t
103 rasound assessment, unselected patients with intermittent claudication requesting treatment for claud
104 e typically not revealed until symptoms like intermittent claudication, rest pain and ischemic gangre
107 rhinitis without asthma was associated with intermittent claudication (RRR:4.63, 95% CI:1.72-12.5),
109 ient ischemic attack or stroke, a history of intermittent claudication, stenosis of 80 to 94 percent
110 ial with the aim to enroll 320 patients with intermittent claudication that does not respond to medic
111 cclusive peripheral arterial disease include intermittent claudication, that is, pain with walking, a
112 ion) randomized patients with mild-to-severe intermittent claudication to either revascularization +
113 [8] years; 87% male, 37% with diabetes) with intermittent claudication were enrolled at medical cente
114 patients with peripheral artery disease with intermittent claudication who have not responded to medi
115 ficantly by presentation; from patients with intermittent claudication who should undergo structured
116 ery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of per
117 ts with peripheral artery disease experience intermittent claudication, with consequent loss of quali